As new therapies for obesity enter the market, biopharmaceutical companies will need to tune commercial strategies to win ...

Executive coach Joel Garfinkle shares tips to help "quiet" life science leaders assert themselves and move from invisible to ...

Twenty years ago, Roger Cone, Ph.D. made a key discovery in obesity science which could help Courage Therapeutics deliver ...

On this weeks Business of Biotech episode, Ebrahim Delpassand, M.D., founder, CEO, and chairman of the board at RadioMedix talks about his personal journey standing up and growing a ...

Catalyst Flex, a functional service provider (FSP) solution of Catalyst Clinical Research, is a multi-therapeutic niche contract research organization (CRO)with flexible, fit-for-purpose offerings in ...

On this weeks Business Of Biotech episode, Oury Chetboun, co-founder and CEO of Seekyo, a French biotech, talks about the range of experiences that prepared him to lead a company focused on developing ...

Life sciences companies can look to the automotive industry for ideas about collaborating with patients to co-create new ...

Because of the unknowns around revenue streams, biotech valuation may appear to be more guesswork than science. However, common valuation methods can help account for some of the product-line ...

Lisa Conte’s idea was to do more efficient drug discovery and development by leveraging the knowledge of “traditional healers.” However, like most entrepreneurial climbs, it would ...

Trade secrets protect innovation by keeping that innovation secret. But trade secret protection is lost once the trade secret becomes known to the public. Biotechs should have a strategic plan for ...

Advocacy for alternatives to animal testing in clinical research is pushing the industry away from animal-based endotoxin testing. Charles River Labs Nicola Reid lays out the issues to consider.

Chris Anzalone, CEO of Arrowhead Pharmaceuticals, discusses overcoming adversity while leading the company through challenging times.